Xofigo (radium Ra-223 dichloride) / Bayer - LARVOL DELTA

Uncommon penile metastasis emerges in patient with mCRPC during Radium223 radioligand therapy : A Rare Case Highlighted by PSMA PET/CT (EANM 2025) - "In 2021 he developed mCRPC and received several lines of treatment, including hormone therapy (enzalutamide), chemotherapy (docetaxel), targeted therapy (olaparib), 177Lu PSMA 617 RLT and was referred in January 2025 for Radium 223 RLT. Despite its rarity, penile metastasis can emerge in advanced stages, and advanced imaging plays a critical role in detecting such atypical sites. Due to the poor prognosis, early detection and subsequent palliative treatment are essential, particularly in cases of extensive disease spread."

Clinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Palliative care • Prostate Cancer • Solid Tumor • BRCA2

Assessment of Sequential Radium-223 and Docetaxel Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer: Insights from the Global REASSURE Study (EANM 2025) - "Radium-223 was concomitantly administered with abiraterone (R-D: 22%; D-R:8%) or enzalutamide (R-D: 22%; D-R: 11). Conclusion Despite differences in key baseline demographics, OS from first drug in the sequence was similar between R-D and D-R. Overall safety and treatment completion were more favorable in the R-D sequence, highlighting the importance of patient selection to optimizing patient outcomes."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

The Effectiveness of Radium-223 on Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis (EANM 2025) - "Conclusion This meta-analysis demonstrates that radium-223 therapy, particularly when administered in combination with other systemic treatments, is associated with improved OS and PFS in patients with mCRPC. An improvement in OS was also observed among patients who completed 5–6 cycles of radium-223 treatment."

Metastases • Retrospective data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Radium-223 (Xofigo) for the treatment of metastatic castration-resistant prostate cancer: our experience. (EANM 2025) - "Our results suggest that Xofigo achieves good symptomatic control with clinical improvement or stabilization in nearly 70% of patients, despite the lack of radiological improvement. Lower initial body weight is associated with a higher rate of treatment discontinuation and mortality."

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Musculoskeletal Pain • Oncology • Prostate Cancer • Solid Tumor

Radiolabelled alginate nanoparticles - developing a peptide targeting radiotherapeutic approach to cancer treatment (EANM 2025) - "In addition to 225 Ac, we have shown that alginate nanoparticles can also chelate radium-223 and its decay daughters (Figure 5)...225 Ac labelled RGD-alginate nanoparticles are now undergoing preclinical testing in a rodent model of glioblastoma. Supported by grant 346303 ALPHAGLIO from the Research Council of Norway."

Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

Dual-locked targeted alpha-emitter enhanced tumor immunotherapy via Diels-Alder reaction-based self-immolative molecular cage strategy (EANM 2025) - "However, the clinical translation of alpha-emitters, particularly radium-223 ( 223 Ra), remains challenging due to inefficient targeted delivery and uncontrolled release of recoil daughter products, leading to systemic toxicity...Furthermore, when combined with PD-L1 blockade, this strategy significantly enhances systemic antitumor immunity, leading to robust inhibition of tumor growth and metastasis. Conclusion These findings underscore the potential of dual-locked pretargeted strategies to advance TAT by improving therapeutic efficacy and addressing the critical challenge of radionuclide leakage, paving the way for next-generation precision-targeted radiopharmaceuticals."

Oncology

Baseline Bone Marrow Scintigraphy as Predictive Marker of Outcomes in mCRPC Patients Treated with Radium-223 Dichloride (EANM 2025) - "Patients with BM expansion have worse outcomes compared to those with normal BM. The study findings also showed a correlation between the BM expansion and baseline clinical and biological factors in mCRPC."

Biomarker • Clinical • Castration-Resistant Prostate Cancer • Prostate Cancer

Fracture risk and treatments at progression in EORTC-1333 PEACE-3 study evaluating the addition of Radium 223 in metastatic castration-resistant prostate cancer starting enzalutamide (EANM 2025) - No abstract available

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Musculoskeletal Diseases • Oncology • Prostate Cancer • Solid Tumor

Radium-223-Loaded Radioactive Metal-Organic Framework Induces Alpha-Particle-Driven PANoptosis to Halt Cancer Progression (EANM 2025) - No abstract available

Oncology

811 Special Symposium 3 - Dosimetry Committee: Challenges in Dosimetry of Alpha-Emitters (EANM 2025) - "In this session, some issues related to dosimetry with alpha emitters that should be known before starting with it are addressed. These issues are the lack of validated primary and secondary standards associated with the measurement of alpha emitters in radionuclide calibrators, the feasibility of SPECT–based dosimetry of alpha emitters, the trouble of daughters’ redistribution and the need of performing small scale dosimetry or microdosimetry to better understand treatment effect in some circumstances."

Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Radium-223 Through the Ages: From Discovery to Modern Applications (EANM 2025) - No abstract available

Investigation of the Safety of Radium-223 Chloride in Combination with External Beam Radiotherapy for Bone Metastases of Prostate Cancer (ASTRO 2025) - No abstract available

Clinical • Combination therapy • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Workshop 02 - Moving Beyond the Basics: Implementation of a Radiopharmaceutical Therapy Program (ASTRO 2025) - "Specifically, Radium-223, Lutetium-177 dotatate and Lutetium-177 PSMA-617 will be discussed. Identify clinical indications for RPTs that are currently approved for clinical use. Identify logistical steps and common challenges in implementing RPT use in their own practice."

Oncology

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (clinicaltrials.gov) - P2 | N=134 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Medullary Carcinoma • Oncology • Papillary Renal Cell Carcinoma • Renal Cell Carcinoma • Solid Tumor

Bone Fractures and Prior Abiraterone Use in Men Treated with Radium-223 and Enzalutamide Combination for Castration Resistant Prostate Cancer (CRPC) with Bone Metastases(m): A Real-World Observational Study (ESMO 2025) - No abstract available

Clinical • Observational data • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Real-World Experience with Radium-223 in Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study (ESMO 2025) - No abstract available

Metastases • Real-world • Real-world evidence • Retrospective data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Ten-Year Perspective on Radium-223 (Ra-223) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Survival, Symptom Control, and Lessons Learned. (ESMO 2025) - No abstract available

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

LuRa: Efficacy and Tolerability of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. (ESMO 2025) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Real-World Experience with Radium-223 Dichloride in mCRPC: A Single-Center Retrospective Analysis (ESMO 2025) - No abstract available

Real-world • Real-world evidence • Retrospective data • Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer

Combined treatment with radium-223 (RAD) and enzalutamide (ENZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): insights from the global REASSURE study (ESMO 2025) - No abstract available

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial (ESMO 2025) - No abstract available

Clinical • Metastases • P1/2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Key takeaways from the COMRADE trial in CRPC, with Rana McKay, MD (Urology Times) - "In a recent interview with Urology Times, presenting author Rana R. McKay, MD, FASCO, walked through the key findings and notable takeaways from the study. McKay noted that although it is unlikely that the combination of olaparib plus radium-223 will advance to a phase 3 trial, these results open the door for more combination DNA damaging agents in this setting."

Interview

Chimeric Antigen Receptor-Engineered (CAR)-T Cell Therapy for Metastatic Prostate Cancer. (PubMed, Cancer Lett) - "These include androgen receptor signaling inhibitors such as enzalutamide and abiraterone acetate, taxane-based chemotherapies including docetaxel and cabazitaxel, and bone-targeting radiopharmaceuticals like radium-223. Immunotherapeutic agents have also contributed to expanding treatment options with Sipuleucel-T, a dendritic cell-based vaccine, and pembrolizumab, a PD-1 immune checkpoint inhibitor approved for select patient populations. Furthermore, the introduction of poly (ADP-ribose) polymerase inhibitors like olaparib and rucaparib, has transformed the therapeutic landscape, particularly for patients with DNA repair deficiencies in metastatic prostate cancer...In this review, we highlight adoptive cellular therapies utilizing CAR-T cells engineered to recognize prostate cancer-specific antigens, aiming to overcome immune evasion mechanisms. We summarize current CAR-T modalities with their limitations and prospects being evaluated in both preclinical and clinical..."

Journal • Review • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Neuroendocrine Tumor • Oncology • Prostate Cancer • Solid Tumor • DRD

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: University of Southern California | Trial completion date: Nov 2025 ➔ Nov 2027 | Trial primary completion date: Nov 2024 ➔ Nov 2026

Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Management of Metastatic Prostate Cancer. (PubMed, Oncol Res Treat) - "The growing number of treatment options and a better understanding of the biological processes involved in tumor progression and the development of resistance are enabling increasingly individualized treatment of patients with advanced PCa."

Journal • Review • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor